DK2812004T3 - COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY - Google Patents

COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY Download PDF

Info

Publication number
DK2812004T3
DK2812004T3 DK13747100.9T DK13747100T DK2812004T3 DK 2812004 T3 DK2812004 T3 DK 2812004T3 DK 13747100 T DK13747100 T DK 13747100T DK 2812004 T3 DK2812004 T3 DK 2812004T3
Authority
DK
Denmark
Prior art keywords
pyrido
pyrimidin
pyrazin
methyl
pyridin
Prior art date
Application number
DK13747100.9T
Other languages
Danish (da)
English (en)
Inventor
Hongyan Qi
Amal Dakka
Gary Mitchell Karp
Jana Narasimhan
Nikolai Naryshkin
Anthony A Turpoff
Ellen Welch
Matthew G Woll
Tianle Yang
Nanjing Zhang
Xiaoyan Zhang
Xin Zhao
Soongyu Choi
Marla L Weetall
Luke Green
Emmanuel Pinard
Hasane Ratni
Original Assignee
Ptc Therapeutics Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2812004(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics Inc, Hoffmann La Roche filed Critical Ptc Therapeutics Inc
Application granted granted Critical
Publication of DK2812004T3 publication Critical patent/DK2812004T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
DK13747100.9T 2012-02-10 2013-02-08 COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY DK2812004T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597523P 2012-02-10 2012-02-10
PCT/US2013/025292 WO2013119916A2 (en) 2012-02-10 2013-02-08 Compounds for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
DK2812004T3 true DK2812004T3 (en) 2018-10-15

Family

ID=48948163

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13747100.9T DK2812004T3 (en) 2012-02-10 2013-02-08 COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY

Country Status (29)

Country Link
US (6) US9586955B2 (enExample)
EP (2) EP2812004B1 (enExample)
JP (2) JP6092897B2 (enExample)
KR (2) KR102341596B1 (enExample)
CN (3) CN119528903A (enExample)
AR (1) AR092794A1 (enExample)
AU (2) AU2013216870B2 (enExample)
BR (1) BR112014019750B1 (enExample)
CA (1) CA2863874C (enExample)
CL (1) CL2014002100A1 (enExample)
CO (1) CO7061082A2 (enExample)
CR (1) CR20140376A (enExample)
DK (1) DK2812004T3 (enExample)
EA (2) EA037123B1 (enExample)
EC (1) ECSP14017269A (enExample)
ES (1) ES2697174T3 (enExample)
HU (1) HUE039779T2 (enExample)
IL (2) IL233959A (enExample)
MA (1) MA35920B1 (enExample)
MX (2) MX354074B (enExample)
NZ (1) NZ628186A (enExample)
PE (1) PE20142364A1 (enExample)
PH (2) PH12018501711B1 (enExample)
PL (1) PL2812004T3 (enExample)
SG (2) SG10201609188WA (enExample)
TR (1) TR201813877T4 (enExample)
TW (2) TWI585085B (enExample)
UA (1) UA116981C2 (enExample)
WO (1) WO2013119916A2 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10327940B2 (en) 2008-11-09 2019-06-25 3D Systems, Inc. Spiral brace
WO2013101974A1 (en) 2011-12-30 2013-07-04 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
JP6193888B2 (ja) 2012-01-26 2017-09-06 ピーティーシー セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
NZ628186A (en) * 2012-02-10 2016-03-31 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
WO2013130689A1 (en) 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CN104470909B (zh) 2012-03-23 2018-04-24 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
EP2934548A2 (en) * 2012-12-24 2015-10-28 Ramot at Tel-Aviv University Ltd Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
BR112015032718A2 (pt) 2013-08-19 2019-09-17 Hoffmann La Roche composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
PL3663296T3 (pl) 2014-05-15 2023-08-07 F. Hoffmann-La Roche Ag Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
JP6867945B2 (ja) 2014-10-03 2021-05-12 コールド スプリング ハーバー ラボラトリー 核内遺伝子出力の標的とされた増強
JP6831324B2 (ja) * 2014-11-01 2021-02-17 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド 特定のタンパク質キナーゼ阻害剤
WO2016111896A1 (en) * 2015-01-05 2016-07-14 Sikorsky Aircraft Corporation Integrated vibration damper for additively manufactured structure and method
CN107635999B (zh) * 2015-05-20 2020-09-25 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
WO2017060731A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
AU2016353961B2 (en) * 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
CN108137601A (zh) * 2015-11-12 2018-06-08 豪夫迈·罗氏有限公司 用于治疗肌萎缩性侧索硬化症的化合物
SI3386591T1 (sl) 2015-12-09 2020-11-30 Cadent Therapeutics, Inc. Heteroaromatski NMDA receptorski modulatorji in njihove uporabe
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
KR20220100719A (ko) 2015-12-10 2022-07-15 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
AU2016370653A1 (en) 2015-12-14 2018-06-21 Cold Spring Harbor Laboratory Antisense oligomers for treatment of Autosomal Dominant Mental Retardation-5 and Dravet Syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
EP3448861B1 (en) 2016-04-28 2021-04-21 F. Hoffmann-La Roche AG A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
EP3471779A4 (en) 2016-06-16 2020-07-08 Ionis Pharmaceuticals, Inc. COMBINATIONS FOR MODULATING SMN EXPRESSION
EP3544435A4 (en) * 2016-11-28 2020-11-04 PTC Therapeutics, Inc. RNA SPLICE MODULATION PROCESSES
JP7332472B2 (ja) * 2016-12-22 2023-08-23 ノバルティス アーゲー Nmda受容体モジュレーターおよびその使用
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CA3065547A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
BR112019027719A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
EP3644996B1 (en) * 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
JP7312749B2 (ja) 2017-08-04 2023-07-21 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
LT3673080T (lt) 2017-08-25 2023-12-27 Stoke Therapeutics, Inc. Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
WO2019057740A1 (en) * 2017-09-22 2019-03-28 F. Hoffmann-La Roche Ag PROCESS FOR THE PREPARATION OF 7- (4,7-DIAZASPIRO [2.5] OCTAN-7-YL) -2- (2,8-DIMETHYLIMIDAZO [1,2-B] PYRIDAZIN-6-YL) PYRIDO [1,2-DERIVATIVES] ] pyrimidin-4-ONE
US20210268667A1 (en) 2017-10-23 2021-09-02 Stoke Therapeutics, Inc. Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
EA202190116A1 (ru) * 2018-06-27 2021-08-30 Реборна Биосайенсиз, Инк. Агент для профилактики или лечения спинальной мышечной атрофии
CN112805280B (zh) 2018-06-27 2024-12-06 Ptc医疗公司 用于治疗亨廷顿氏病的杂芳基化合物
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
MX2021001367A (es) 2018-08-03 2021-06-23 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromático y usos de los mismos.
WO2020033473A1 (en) * 2018-08-07 2020-02-13 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
WO2021021775A1 (en) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
CN110540535B (zh) * 2019-10-23 2020-07-31 上海再启生物技术有限公司 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法
CN111116576A (zh) * 2019-12-01 2020-05-08 北京师范大学 一种喹嗪酮类化合物及其制备方法
BR112022010561A2 (pt) 2019-12-02 2022-11-16 Storm Therapeutics Ltd Compostos poli-heterocíclicos como inibidores de mettl3
BR112022014635A2 (pt) 2020-01-28 2022-10-11 Protego Biopharma Inc Compostos, composições e métodos para estabilizar transtirretina e inibir mau dobramento de transtirretina
JP7728772B2 (ja) * 2020-02-12 2025-08-25 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法
CA3169676A1 (en) 2020-02-28 2021-09-02 Dominic Reynolds Compounds and methods for modulating splicing
EP4110775A1 (en) 2020-02-28 2023-01-04 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
IL295957A (en) 2020-02-28 2022-10-01 Remix Therapeutics Inc Compounds and methods for modulating splicing
WO2021174170A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
PH12022552258A1 (en) 2020-02-28 2023-11-20 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2
TW202208344A (zh) 2020-04-08 2022-03-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
WO2021207530A1 (en) 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
EP4150092A4 (en) 2020-05-11 2024-11-06 Stoke Therapeutics, Inc. OPA1 ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS
KR20230118067A (ko) 2020-07-02 2023-08-10 레믹스 테라퓨틱스 인크. 5-[5-(피페리딘-4-일)티에노[3,2-c]피라졸-2-일]인다졸 유도체, 및 핵산 스플라이싱의 조절제로서의 및 증식성 질환의 치료를 위한 관련 화합물
BR112022027107A2 (pt) 2020-07-02 2023-03-14 Remix Therapeutics Inc Derivados de 2-(indazol-5-il)-6-(piperidin-4-il)-1,7-naftiridina e compostos relacionados como moduladores para splicing de ácidos nucleicos e para o tratamento de doenças proliferativas
WO2022070071A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
CR20230437A (es) 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
WO2023009585A2 (en) 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds
WO2023034811A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
EP4395889A1 (en) 2021-08-30 2024-07-10 Remix Therapeutics Inc. Compounds and methods for modulating splicing
EP4396177A1 (en) 2021-08-30 2024-07-10 Remix Therapeutics Inc. Compounds and methods for modulating splicing
EP4395890A1 (en) 2021-08-30 2024-07-10 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034812A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240366612A1 (en) 2021-10-13 2024-11-07 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
TW202333689A (zh) 2021-10-13 2023-09-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
US20250109140A1 (en) 2022-01-05 2025-04-03 Remix Theraputics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
US20250092065A1 (en) 2022-01-05 2025-03-20 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
TW202346305A (zh) 2022-01-05 2023-12-01 美商雷密克斯醫療公司 用於調節剪切之化合物及方法
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
AU2024286618A1 (en) * 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
CN117263936B (zh) * 2023-11-21 2024-02-23 中国中医科学院医学实验中心 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558618A (en) * 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JPS56150091A (en) 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5599816A (en) * 1990-05-02 1997-02-04 Abbott Laboratories Quinolizinone type compounds
EP0640083A1 (en) * 1992-05-13 1995-03-01 E.I. Du Pont De Nemours And Company Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides
EP0871628A1 (en) * 1995-06-06 1998-10-21 Abbott Laboratories Quinolizinone type compounds
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
WO2000017197A1 (en) * 1998-09-21 2000-03-30 Biochem Pharma Inc. Quinolizinones as integrin inhibitors
HK1048114A1 (en) * 1999-10-28 2003-03-21 基本治疗公司 Drug discharge pump inhibitors
CA2398163C (en) * 2000-01-24 2011-02-22 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
CA2665516A1 (en) 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
EP1474147B1 (en) 2001-12-07 2010-05-05 Vertex Pharmaceuticals Incorporated Pyrimidine-based compounds useful as gsk-3 inhibitors
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
AU2004249730A1 (en) * 2003-06-20 2004-12-29 Novartis Vaccines And Diagnostics, Inc. Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents
WO2005105801A1 (en) 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
WO2008013997A2 (en) 2006-07-27 2008-01-31 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2011062853A1 (en) * 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
EP2523956A1 (en) * 2010-01-13 2012-11-21 Institut Pasteur Korea Anti - infective pyrido (1,2 -a) pyrimidines
WO2013101974A1 (en) 2011-12-30 2013-07-04 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
JP6193888B2 (ja) 2012-01-26 2017-09-06 ピーティーシー セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
NZ628186A (en) * 2012-02-10 2016-03-31 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
WO2013130689A1 (en) 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CN104470909B (zh) 2012-03-23 2018-04-24 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
PL3663296T3 (pl) 2014-05-15 2023-08-07 F. Hoffmann-La Roche Ag Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni
CN107635999B (zh) 2015-05-20 2020-09-25 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物

Also Published As

Publication number Publication date
US20170129885A1 (en) 2017-05-11
TWI629274B (zh) 2018-07-11
EP2812004B1 (en) 2018-06-27
PE20142364A1 (es) 2015-01-10
MX2014009696A (es) 2015-01-14
TR201813877T4 (tr) 2018-11-21
NZ628186A (en) 2016-03-31
JP6363744B2 (ja) 2018-07-25
MA35920B1 (fr) 2014-12-01
IL254045B (en) 2019-05-30
TW201336842A (zh) 2013-09-16
JP6092897B2 (ja) 2017-03-08
JP2017122097A (ja) 2017-07-13
EP2812004A2 (en) 2014-12-17
CO7061082A2 (es) 2014-09-19
ES2697174T3 (es) 2019-01-22
IL233959A0 (en) 2014-09-30
EP3406252A1 (en) 2018-11-28
ECSP14017269A (es) 2015-09-30
CR20140376A (es) 2015-01-23
AU2017204248B2 (en) 2019-05-30
TWI585085B (zh) 2017-06-01
PH12018501711B1 (en) 2023-05-05
US20150005289A1 (en) 2015-01-01
US20190375750A1 (en) 2019-12-12
KR20200093066A (ko) 2020-08-04
WO2013119916A2 (en) 2013-08-15
US20180105526A1 (en) 2018-04-19
BR112014019750B1 (pt) 2020-03-03
IL233959A (en) 2017-11-30
US20210276999A1 (en) 2021-09-09
EA201491505A1 (ru) 2015-01-30
US9586955B2 (en) 2017-03-07
AU2017204248A1 (en) 2017-07-13
CL2014002100A1 (es) 2015-10-23
IL254045A0 (en) 2017-10-31
PL2812004T3 (pl) 2019-01-31
KR102341596B1 (ko) 2021-12-21
CN104349777A (zh) 2015-02-11
HK1202077A1 (en) 2015-09-18
US9879007B2 (en) 2018-01-30
US20240067646A1 (en) 2024-02-29
HUE039779T2 (hu) 2019-02-28
EA037123B1 (ru) 2021-02-09
CA2863874C (en) 2021-02-16
BR112014019750A2 (pt) 2017-06-20
PH12018501711A1 (en) 2019-09-23
KR102137087B1 (ko) 2020-07-24
CN119528903A (zh) 2025-02-28
PH12014501786A1 (en) 2014-11-10
JP2015508075A (ja) 2015-03-16
EA201792465A1 (ru) 2018-08-31
US11753407B2 (en) 2023-09-12
EP3406252B1 (en) 2020-05-13
MX354074B (es) 2018-02-12
WO2013119916A3 (en) 2013-10-24
CN104349777B (zh) 2018-05-01
AU2013216870B2 (en) 2017-07-20
US10851101B2 (en) 2020-12-01
EP2812004A4 (en) 2015-11-11
AR092794A1 (es) 2015-05-06
SG11201404713PA (en) 2014-09-26
CN108299314A (zh) 2018-07-20
MX2022011699A (es) 2022-11-09
BR112014019750A8 (pt) 2018-01-16
KR20140121482A (ko) 2014-10-15
UA116981C2 (uk) 2018-06-11
CN108299314B (zh) 2024-11-26
CA2863874A1 (en) 2013-08-15
PH12014501786B1 (en) 2014-11-10
SG10201609188WA (en) 2016-12-29
AU2013216870A1 (en) 2014-08-28
TW201722942A (zh) 2017-07-01
EA029542B1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
US11753407B2 (en) Compounds for treating spinal muscular atrophy
KR102057351B1 (ko) 척수성 근위축증을 치료하기 위한 화합물
KR102064624B1 (ko) 척수성 근위축증을 치료하기 위한 화합물
KR20140131384A (ko) 척수성 근위축증을 치료하기 위한 화합물
BR112014016443B1 (pt) Mistura de pó e método de fabricação de um componente sinterizado
HK40005163A (en) Compounds for treating spinal muscular atrophy
HK40005163B (en) Compounds for treating spinal muscular atrophy
HK1202077B (en) Compounds for treating spinal muscular atrophy